Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

In acutely ill patients, 10 days of rivaroxaban was noninferior to 10 days of enoxaparin for thromboprophylaxis. Extended-duration rivaroxaban treatment (35 days) reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. Patients with active cancer, s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine Jg. 368; H. 6; S. 513 - 523
Hauptverfasser:	Cohen, Alexander T, Spiro, Theodore E, Büller, Harry R, Haskell, Lloyd, Hu, Dayi, Hull, Russell, Mebazaa, Alexandre, Merli, Geno, Schellong, Sebastian, Spyropoulos, Alex C, Tapson, Victor
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Waltham, MA Massachusetts Medical Society 07.02.2013
Schlagworte:	Acute Disease Administration, Oral Adult Aged Anticoagulants Anticoagulants - adverse effects Anticoagulants - therapeutic use Asymptomatic Biological and medical sciences Double-Blind Method Drug Administration Schedule Enoxaparin Enoxaparin - adverse effects Enoxaparin - therapeutic use Factor Xa Factor Xa Inhibitors Female General aspects Heart attacks Hemorrhage Hemorrhage - chemically induced Hospitalization Humans Injections, Subcutaneous Life Sciences Male Medical sciences Middle Aged Morpholines Morpholines - adverse effects Morpholines - therapeutic use Prevention and actions Public health. Hygiene Public health. Hygiene-occupational medicine Pulmonary embolisms Rivaroxaban Thiophenes Thiophenes - adverse effects Thiophenes - therapeutic use Thromboembolism Thrombosis Ultrasonic imaging Veins & arteries Venous Thromboembolism Venous Thromboembolism - epidemiology Venous Thromboembolism - prevention & control Vascular disease Human Medicine Prevention Rivaroxaban Antithrombotic agent Cardiovascular disease Patient Thrombosis
ISSN:	0028-4793, 1533-4406, 1533-4406
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!